Is KPV legal?
Not approved · not compoundable- FDA status
- KPV is not FDA approved. It was moved off FDA’s Category 2 safety-risk list in 2026 after its nomination was withdrawn, but it was not added to the 503A bulks list.
- Compounding
- That leaves no routine legal path for a US compounding pharmacy to prepare it. FDA’s Pharmacy Compounding Advisory Committee discussed it in July 2026; FDA had not announced a decision as of October 2026.
- Prescription
- There is no approved US prescription product for KPV.
- Online market
- Products sold online are labelled “for research use only”: not made, tested or labelled for human use, and often mislabelled.
US status checked October 2026 against FDA’s compounding lists. Sources at the foot of the page.
What is KPV?
KPV is a tiny peptide made of just three amino acids: lysine, proline and valine. It is the final three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH), a natural hormone best known for darkening skin. Alpha-MSH also calms inflammation, and in the 1990s researchers found that this short tail piece kept much of that anti-inflammatory effect on its own.6 Alpha-MSH is present in barrier organs such as the gut and skin, which suggests it is part of the body's built-in defense at those surfaces.3
KPV is not an approved drug and has not been tested in a published human clinical trial. It is sold online as a research chemical and offered by some wellness clinics. It is marketed mainly for gut inflammation, such as inflammatory bowel disease, and for skin conditions. It also turns up in bodybuilding and recovery circles.2
- Anecdotal only
- In vitro only
- Animal models only
- Preliminary human
- Clinical trials
- Regulator approved
How KPV works
Inflammation is driven partly by a master switch inside cells called NF-kB. When it flips on, cells pump out signaling proteins that recruit immune cells and cause swelling and tissue damage. Alpha-MSH turns that switch down.1 KPV appears to do something similar. Researchers have described three routes for alpha-MSH and fragments such as KPV: direct effects on cells at the site of inflammation, effects on immune cells inside the brain, and nerve pathways from the brain that calm inflammation elsewhere in the body.1
The interesting part is what KPV does not do. Full alpha-MSH acts on melanocortin receptors, including the one that causes tanning. KPV is too short to bind those receptors, so it does not affect skin color, yet it keeps almost all of the parent hormone's anti-inflammatory activity in lab and animal models.4
In more precise terms, the exact signaling route for KPV is still unknown, though it shares features with alpha-MSH's anti-inflammatory signaling, including effects on NF-kB activation, adhesion molecules and inflammatory cytokines.4 Mouse studies suggested that KPV is taken up into the cells lining the gut by a peptide transporter called PepT1, which may explain why it seemed to work when given by mouth in colitis models. Alpha-MSH fragments, including the 11-13 tripeptide, also reduced the inflammatory signal TNF-alpha in human brain support cells grown in the lab.8
Repair peptides are said to act on blood-vessel growth and cell migration in the proliferation stage. Most of that evidence comes from animal studies.
What the research shows on KPV
All evidence on KPV comes from cell studies and animal models. No controlled human trial has been published.
The animal and cell evidence is fairly broad. Alpha-MSH and its tripeptide were effective across major laboratory models of inflammation, including experimental inflammatory bowel disease and brain inflammation triggered by bacterial toxins.6 In lab tests, both alpha-MSH and KPV inhibited the bacterium Staphylococcus aureus and the yeast Candida albicans.3 More recent work packaged KPV into hydrogels, which reduced inflammation, supported tissue repair and helped fight MRSA in wound models.5
Interest in gut disease continues. A 2025 review grouped KPV with host defense peptides being explored as new leads for inflammatory bowel disease, mainly because they dampen NF-kB signaling and inflammatory cytokines.7 That is a statement of potential, not proven benefit.
Much of the foundational work dates from the late 1990s and early 2000s. More than two decades later, KPV still has no published efficacy trial in people. The limits matter. Mouse colitis is a model, not Crohn's disease or ulcerative colitis. Doses, routes and formulations differ between studies. A related tripeptide, KdPT, has drawn similar research interest,4 but neither has a published efficacy trial in people. Until human trials exist, claims that KPV heals the gut or treats IBD are not supported.
Studied for: Inflammatory bowel research, Skin inflammation, Gut barrier research.
KPV reference data
| Sequence | KPV |
|---|---|
| Molecular weight | 342.44 Da |
| FDA status | Not approved for any indication. |
| Prohibited in sport | Not listed |
KPV dosage in published research
1-2x daily · usually run for about 8 weeks. A reference pattern, not a prescription.
Open this in the dosage calculator ↗
How KPV is used in practice
KPV has no approved medical use. Some functional medicine and wellness clinics have offered it as capsules, injections or topical creams, often for gut symptoms, food sensitivities or skin inflammation. Compounding access is restricted because of FDA concerns about bulk peptides, so availability through clinics varies.
Most KPV is bought online as a "research use only" powder, oral capsules or nasal sprays. These products are not made to pharmaceutical standards. Reviews of the peptide market report that products are often mislabeled or contaminated.2 Oral products face an extra question: whether enough intact peptide reaches the gut lining depends on formulation, and most retail products have not been tested for that.
KPV risks and side effects
Because there are no published human trials, the side effect profile is not established. Users report mild effects such as injection-site reactions and stomach upset. Allergic reactions are possible with any peptide.
The bigger risk for people with inflammatory bowel disease is substitution. Crohn's disease and ulcerative colitis can cause strictures, bleeding and lasting bowel damage if not properly controlled. Replacing proven treatment with an unproven peptide can let the disease progress quietly.
Because KPV dampens inflammation, it could in theory blunt normal immune responses, but this has not been studied in people. Interactions with immunosuppressants and biologic drugs are unknown. Some people take KPV in "gut healing" stacks with BPC-157 or other peptides, which multiplies the unknowns and makes any side effect hard to trace. It should not be used in pregnancy. Product quality is a separate risk, from wrong content to bacterial contamination in injectable vials.
Reported side effects
Alternatives to KPV
For inflammatory bowel disease, approved and well-studied options include mesalamine, corticosteroids such as budesonide, immunomodulators such as azathioprine, and biologics and small molecules such as infliximab, adalimumab, vedolizumab, ustekinumab and tofacitinib. A gastroenterologist can match treatment to disease type and severity.
For inflammatory skin conditions, topical corticosteroids, calcineurin inhibitors and, for moderate to severe disease, biologics such as dupilumab have strong trial evidence. For general gut symptoms without a diagnosis, the first step is a proper workup rather than an experimental peptide.
The bottom line on KPV
KPV is a scientifically interesting fragment of a natural anti-inflammatory hormone, with consistent results in cell and animal studies. But there are no published human trials, product quality is unverified, and the conditions it is marketed for have effective approved treatments. It belongs in research, not in place of proven care.
Questions for a clinician
- What evidence applies to my situation, and at what level?
- What established alternatives should I consider first?
- What monitoring would be necessary, and how often?
- Can this be prescribed at all where I live, or only sold for research?
KPV FAQ
What is KPV?
The C-terminal tripeptide of alpha-MSH, which keeps the anti-inflammatory activity without the pigmentation effects. It is classed as healing & repair.
Is KPV FDA approved?
No. KPV is not approved by the FDA for any indication. Material sold online is labelled for research use only.
Is KPV legal in the US?
KPV is not FDA approved. It was moved off FDA’s Category 2 safety-risk list in 2026 after its nomination was withdrawn, but it was not added to the 503A bulks list. That leaves no routine legal path for a US compounding pharmacy to prepare it. FDA’s Pharmacy Compounding Advisory Committee discussed it in July 2026; FDA had not announced a decision as of October 2026.
What dose of KPV is used in research?
Published research and practitioner protocols report 200-500 mcg, 1-2x daily, typically for 8 weeks. This is a reference range, not a recommendation; dosing should be set by a licensed clinician.
How is KPV reconstituted?
A 5 mg vial mixed with 2 mL of bacteriostatic water gives 2.5 mg/mL. At that concentration 200 mcg is 8.0 units on a 100-unit insulin syringe.
What are the side effects of KPV?
Reported side effects include injection-site reactions, mild gastrointestinal upset. Contraindications: pregnancy, known hypersensitivity.
What is the half-life of KPV?
The reported half-life of KPV is ~1-2 hours.
Is KPV banned in sport?
KPV is not specifically named on the WADA prohibited list, but athletes should check the current list and their federation's rules.
References
Regulatory and primary sources
- FDA: Bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) ↗ · content current as of April 22, 2026; checked October 18, 2026
- FDA: Bulk drug substances used in compounding under section 503A ↗ · how the 503A categories work
- PubChem compound record (CID 13294447) ↗ · structure, identifiers, synonyms
- FDA: Unapproved drugs and "research use only" products ↗ · regulatory status of non-approved products
Published literature
- The neuroimmunomodulatory peptide alpha-MSH.Ann N Y Acad Sci 2000.PubMed 11268347 · doi:10.1111/j.1749-6632.2000.tb05386.x
- A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.J Sports Med Phys Fitness 2026.PubMed 41880199 · doi:10.23736/S0022-4707.26.17773-1
- The neuropeptide alpha-MSH in host defense.Ann N Y Acad Sci 2000.PubMed 11268348 · doi:10.1111/j.1749-6632.2000.tb05387.x
- Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore.Adv Exp Med Biol 2010.PubMed 21222263 · doi:10.1007/978-1-4419-6354-3_8
- Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review.Int J Med Sci 2025.PubMed 41209547 · doi:10.7150/ijms.118118
- Mechanisms of antiinflammatory action of the neuroimmunomodulatory peptide alpha-MSH.Ann N Y Acad Sci 1998.PubMed 9629264 · doi:10.1111/j.1749-6632.1998.tb09576.x
- Host defense peptides as a new drug lead to a strategy for inflammatory bowel disease.Drug Discov Today 2025.PubMed 41241376 · doi:10.1016/j.drudis.2025.104535
- Peptide modulation of inflammatory processes within the brain.Neuroimmunomodulation 1998.PubMed 9730684 · doi:10.1159/000026335
Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.